Photobiomodulation for

Parkinson's Disease

According to the NHS, more than 10 million people worldwide are living with Parkinson’s disease (PD), and the incidence of the disease increases with age.

Parkinson’s disease (PD) is a neurodegenerative disorder that affects the central nervous system and body movements. Photobiomodulation therapy (PBM) has shown promising results as a treatment option for individuals diagnosed with Parkinson’s disease (PD).

Photobiomodulation (PBM) can protect dopaminergic neurons and improve measures of mobility, cognition, dynamic balance, and fine motor skills in Parkinson’s disease patients (PD).

In recent clinical trials, photobiomodulation therapy (PBM) has shown to be an effective treatment method for individuals diagnosed with Parkinson’s disease (PD), improving gait speed, stride length, and balance in Parkinson’s patients (Johnstone et al, 2017; Peña et al, 2020) and motor function (Moro et al, 2018).

PBM may be a promising therapy for Parkinson’s disease patients, offering a non-invasive and potentially effective alternative or adjunct therapy.

Research

Near-infrared light has the potential to slow or even stop disease pathology for people with Parkinson’s Disease

Johnstone, D. M. et al. (2015) conducted a review article that discusses the potential of near-infrared light therapy in halting neurodegeneration in Alzheimer's and Parkinson's disease. They suggest that near-infrared light has the potential to be neuroprotective, slowing or even completely stopping disease pathology, with no side effects.
Read more

Transcranial brain stimulation can alter the progression and improvement of neurodegenerative processes

A scientific overview by Nizamutdinov et. al (2022) states that transcranial brain stimulation with near-infrared light in recent animal and human studies revealed a positive impact of treatment on the progression and improvement of neurodegenerative processes, management of brain energy metabolism, and regulation of chronic brain inflammation associated with various conditions, including Parkinson's Disease.
Read more

Improved mobility, cognition, balance, and fine motor skills in people with Parkinson’s Disease

Liebert, A. et al. (2021) study with 12 participants with Parkinson's disease found that 12 weeks of photobiomodulation treatment improved mobility, cognition, balance, and fine motor skills, with many individual improvements lasting for up to one year with sustained home treatment.
Read more

Near-infrared light has the potential to slow or even stop disease pathology for people with Parkinson’s Disease

Johnstone, D. M. et al. (2015) conducted a review article that discusses the potential of near-infrared light therapy in halting neurodegeneration in Alzheimer's and Parkinson's disease. They suggest that near-infrared light has the potential to be neuroprotective, slowing or even completely stopping disease pathology, with no side effects.
Read more

Improved mobility, cognition, balance, and fine motor skills in people with Parkinson’s Disease

Liebert, A. et al. (2021) study with 12 participants with Parkinson's disease found that 12 weeks of photobiomodulation treatment improved mobility, cognition, balance, and fine motor skills, with many individual improvements lasting for up to one year with sustained home treatment.
Read more

Transcranial brain stimulation can alter the progression and improvement of neurodegenerative processes

A scientific overview by Nizamutdinov et. al (2022) states that transcranial brain stimulation with near-infrared light in recent animal and human studies revealed a positive impact of treatment on the progression and improvement of neurodegenerative processes, management of brain energy metabolism, and regulation of chronic brain inflammation associated with various conditions, including Parkinson's Disease.
Read more

References

1. Kitchen LC, Berman M, Halper J, Chazot P. Rationale for 1068 nm Photobiomodulation Therapy (PBMT) as a Novel, Non-Invasive Treatment for COVID-19 and Other Coronaviruses: Roles of NO and Hsp70. Int J Mol Sci. 2022 May 7;23(9):5221. doi: 10.3390/ijms23095221. PMID: 35563611; PMCID: PMC9105035. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105035/

2. Sabino C.P., Ball A.R., Baptista M.S., Dai T., Hamblin M.R., Ribeiro M.S., Santos A.L., Sellera F.P., Tegos G.P., Wainwright M. Light-based technologies for management of COVID-19 pandemic crisis. J. Photochem. Photobiol. B Biol. 2020;212:111999. doi: 10.1016/j.jphotobiol.2020.111999. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435279/

3. Sigman S.A., Mokmeli S., Monici M., Vetrici M.A. A 57-year-old african american man with severe COVID-19 pneumonia who responded to supportive photobiomodulation therapy (PBMT): First use of PBMT in COVID-19. Am. J. Case Rep. 2020;21:e926779. doi: 10.12659/AJCR.926779. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449510/

4. Soheilifar S., Fathi H., Naghdi N. Photobiomodulation therapy as a high potential treatment modality for COVID-19. Lasers Med. Sci. 2020;2020:935–938. doi: 10.1007/s10103-020-03206-9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688201/

5. Vetrici M.A., Mokmeli S., Bohm A.R., Monici M., Sigman S.A. Evaluation of adjunctive photobiomodulation (PBMT) for COVID-19 pneumonia via clinical status and pulmonary severity indices in a preliminary trial. J. Inflamm. Res. 2021;14:965–979. doi: 10.2147/JIR.S301625. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989376/